Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.

Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.

Why Weight Loss Drugs May Not Work

While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:

1. Genetic and Hormonal Variability

Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.

2. Underlying Medical Conditions

Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.

3. Unrealistic Expectations

Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.

Why it is Important to Identify Non-responders

For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.

For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.

Alternative Treatment Options

When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:

1. Switching to Another GLP-1 Drug

For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.

2. Use of Older Medications

While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.

3. Lifestyle Changes

Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.

4. Medical Management of Obesity

It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.

Why Side Effects of Weight Loss Drug Ozempic May Be a Barrier

For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.

Long-term effects of Ozempic or Wegovy on the Brain

Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.

This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.

While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.

The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.

In 2025, Andhra Pradesh reported 1,566 scrub typhus cases, and nine suspected deaths, according to data from the Integrated Health Information Platform, Integrated Disease Surveillance Programme (IDSP-IHIP) on 8 December. Followed by Karnataka with 1,870 cases, Tamil Nadu 7,308 cases, and Telangana, 309 cases. Scrub typhus cases have significantly increased from previous year. It is one of the deadliest infections affecting multiple organs, or even death. Early it was relevant to poeple working in fields, new studies show it migrating to human settlements.

What Is Scrub Typhus?

Scrub typhus, also known as bush typhus, is a bacterial infection caused by bacteria infection, caused by bacterium Orientia tsutsugamushi. It is spread through bites of infected larval mites, Chiggers.

Most cases of scrub typhus occur in rural areas of Southeast Asia, Indonesia, China, Japan, the Indian subcontinent and northern Australia. Until now, it was believed that chiggers only lurked in the tall grasses of remote paddy fields or dense forests. Due to this, it is commonly known as "farmers' disease", only confined to the fields.

However, new PLOS study data revealed the opposite. The study is led by researchers from Christian Medical College (CMC) Vellore and international collaborators and suggests that the bulk of infections are now even occurring within human settlements.

The study monitored over 32 000 people in Tamil Nadu, which led to the conclusion that agricultural activities, long considered the primary risk factor, were only weakly associated with the disease in high-prevalence areas.

How are Human Settlements A Prime Factor?

Risk for scrub typhus is significantly higher for those living in clustered houses or homes with fewer rooms. If the micro environment around the residence is unmaintained, gardens are patched, or even the damp corners of a courtyard, it could lead to breeding ground for the mites and the rodents that carry Chiggers.

Who Is At Most Risk?

It was once believed that working-age men were the most affected, but the new study tells otherwise. According to the new data, women over 60 are at the highest risk of infection.

As women spend most of their time in and around the home, due to household work, from the kitchen to the laundry, these activities are now the primary cross point of contact with infected mites.

What Is the Risk Factor Of Infection?

As initial symptoms of infection, such as fever, headache, and muscle pain, are the same as viral flu or dengue, many first seek help from untrained practitioners or local pharmacies.

By the time they reach the hospital, the disease has already progressed to severe complications like acute respiratory distress syndrome (ARDS), Kidney failure, or Meningoencephalitis, which is inflammation of your meninges and brain at the same time, a life-threatening condition.

Not only this, the researchers revealed that nearly 10 percent of affected households exceed 25 percent of their income in the treatment.

For severe cases, the cost of treatment can be up to approximately INR 110,000, a staggering sum for rural and peri-urban families earning a fraction of that monthly.

Prevention

• Do not let the grass grow tall around your house
• Tightly maintain kitchen gardens and remove piles of wood or debris where rodents (the primary hosts for mites) might nest.
• As chiggers are usually found close to the ground, do not sit directly on the grass or soil. Use chairs or mats. For children, make them wear socks and full- length trousers while playing in the yard.
• If you notice a small, dark, cigarette-burn-like mark, it is usually left behind by mites. It is most likely "Eschar". It is an important critical clue. As the bite is painless, it often goes unnoticed.
• Do a thorough skin check for an eschar, especially in warm, moist areas like the armpits, groin, or behind the knees.

Early intervention is necessary, as if a fever lasts more than two days, don't just treat it as "seasonal fever".

Consult a qualified doctor and specifically ask about scrub typhus. Infection can be treated with doxycycline common antibiotic, in the early stages. The case fatality rate in this study was 1.5 percent, hospital based studies in South India have previously recorded mortality rates as high 30 percent when treatment is delayed

A now-viral video has revealed how a new mother who believed she had grown excessive fat tissue instead discovered that her body had developed a third nipple under her armpit.

Jasmine, an American woman had given birth five days earlier when a lactation consultant visited her to giver her advice on breastfeeding. The new mother, who was still exhausted and recovering from childbirth, recalled mentioning that her armpits always carried what she believed was excess fat that darkened during pregnancy.

"I breastfed my first baby for one-and-a-half-years, so I'm thinking that there's nothing this nurse can say that's going to surprise me," Jasmine said.

However, after a careful examination, the expert told her that the swelling in her underarm was extra breast tissue and that she also had "a nipple” there.

"When you're pregnant, your nipples and areolas will get really dark, and I have noticed the same change with my armpits, so I was like 'Great! extra breast tissue, I already knew that.' And then the lactation consultant is like 'Let me see,' and I show her, and she goes, 'Oh! yeah... And that's a nipple'.

"You know how cows and puppies and kittens, they have that line of nipples? Yeah, humans have that, too. Tell me why she's telling me about someone that had an extra nipple on her thigh. Telling me I have a third nipple in my armpit before I even had my first postpartum poop is diabolical work,” she said, joking about how little sleep she’d had.

What Do Experts Say?

• Polythelia: The third nipple is present by itself with no areola (the area of darker skin around your nipple) or underlying breast tissue. This is the most common type of supernumerary nipple.
• Polythelia areolaris: The have an areola present, but no nipple or breast tissue.
• Polythelia pilosa: The have a patch of hair only.
• Polymastia: The third nipple has an areola and has some underlying breast tissue.
• Supernumerary nipple: There is a third nipple that has breast tissue underneath it, but it doesn’t have an areola.
• Supernumerary nipple: There is some breast tissue and an areola, but no nipple is present.
• Aberrant glandular tissue: You have breast tissue, but no nipple or areola is present.
• Pseudomamma: Your third nipple has an areola around it, but instead of breast tissue, you have fatty tissue beneath

According to Dr Rooma Sinha, an obstetrician and gynaecologist at Apollo Hospitals in Hyderabad, Jasmine's third nipple is known as the axillary tail of the breast, a normal extension of breast glandular tissue that tapers into the underarm.

“Some women have axillary tail of the breast. This is probably that. It may produce milk if it has active mammary glands," she told Moneycontrol .

She also confirmed that humans can have supernumerary nipples along what is known as the “embryonic milk line,” extending from the armpit toward the chest. However, this line does not extend down to the thigh, as Jasmine recalled in her video.

According to experts, the axillary tail can feel like a lump or thickened area, particularly during hormonal changes such as pregnancy, breastfeeding or menstruation and may become tender or enlarged.

What Happened Next?

“Regular breast production is sufficient for me,” she said, noting that the extra tissue was painful and that she might consider surgically removing the tissue after she decides not to have more children.

Even as India is working to roll out a free Human papillomavirus (HPV) vaccination campaign to curb cervical cancer risk, a new global study today revealed that the shot offers sustained protection for up to 18 years.

HPV is one of the most common sexually transmitted infections, and many countries offer vaccination to protect girls against cervical cancer and other related cancers in later life.

The study from Sweden, published by The BMJ, based on 926,362 girls and women between 2006 and 2023, showed that girls vaccinated before age 17 had a substantially (79 percent) lower risk of cervical cancer.

"This study provides evidence of sustained protection against invasive cervical cancer throughout 18 years of follow-up, with no indication of waning protection," said corresponding author Shiqiang Wu, doctoral student at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.

"These findings further support global strategies for eliminating cervical cancer as a public health problem by achieving high coverage of routine HPV vaccination," Wu added.

Early HPV Vaccination Boosts Protection

In the study, 40 percent of participants had received at least one dose of the quadrivalent HPV vaccine.

Of 930 cases identified of invasive cervical cancer, 97 were in vaccinated individuals, while 833 were among the unvaccinated.

Vaccination before age 17 offered higher protection -- 79 percent -- against cervical cancer compared with the unvaccinated group. The protection was sustained with 77 percent lower risk for over 15 years after vaccination, the researchers said.

On the other hand, women vaccinated at age 17 or older had a 37 percent lower risk of invasive cervical cancer compared with the unvaccinated group. Vaccination at an older age led to a 46 percent lower risk of cervical cancer -- about 10–12 years.

The results also show a population-level decline in cervical cancer cases over time.

India's Nationwide Free HPV Vaccine Campaign

Cervical cancer remains the second most common cancer among women in India, with nearly 80,000 new cases and over 42,000 deaths reported annually.

The new nationwide HPV vaccination program will strengthen women's health and eliminate the risks of preventable cervical cancers in the country.

Vaccination under the national program will be voluntary and free of cost.

HPV Vaccine In India: Who Should Take, Where To Get It From

The nationwide program, based on expert recommendations of the National Technical Advisory Group on Immunization (NTAGI), will target girls aged 14 years.

At 14, the HPV vaccine offers maximum preventive benefit, well before potential exposure to the virus.

• Girls aged 9 to 14 should get two doses of the vaccine 6 to 12 months apart
• Women aged 15 to 26 years can get three doses in 0, 2, and 6 months apart
• Adults aged 27 to 45 must get it after consultation with their healthcare provider

The HPV vaccination will be conducted exclusively at designated government health facilities, including Ayushman Arogya Mandirs (Primary Health Centers), Community Health Centers, Sub-District and District Hospitals, and Government Medical Colleges.